Summary
- Profile Type
- Business Offer
- POD Reference
- BOPL20241010007
- Term of Validity
- 10 October 2024 - 10 October 2025
- Company's Country
- Poland
- Type of partnership
- Commercial agreement
- Investment agreement
- Targeted Countries
- All countries
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- A Polish “spin-off” company from Adam Mickiewicz University in Poznan, specialized in biometarials, tissue engineering and 3D bioprinting aims to commercialize the technology of dECM production from various tissues. The technology is scalable, detergent-free, and has been validated on porcine menisci. The company seeks to establish international parterships aiming at commercialization of the dECM-based products.
- Full Description
-
The extracellular matrix (ECM) is a complex, dynamic network of macromolecules, mainly composed of proteins such as collagen, elastin, and fibronectin, as well as glycosaminoglycans and proteoglycans. This intricate structure provides scaffolding and biochemical support to cells within tissues, making it essential for maintaining the structural integrity, function, and communication of tissues throughout the body. However, ECM is not merely a passive framework; it directs and supports numerous processes, such as cell migration, differentiation, proliferation, and tissue regeneration, influencing angiogenesis and tissue remodeling. By utilizing the natural architecture and bioactivity of ECM, dECM-based biomaterials provide biocompatibility, bioactivity, and support for cellular processes, making them ideal for a wide range of medical applications.
dECM-based biomaterials represent the forefront of regenerative medicine and hold immense potential for transforming approaches to tissue repair and regeneration. From wound healing to organ reconstruction, dECM biomaterials offer a natural, biocompatible solution that accelerates regenerative processes and aids in the restoration of functional tissues, ultimately improving patient outcomes and quality of life.
The company has developed a scalable, detergent-free process for ECM extraction and decellularization from animal tissues. This technology has been validated on porcine menisci. The obtained dECM was successfully methacrylated and formulated into UV-crosslinkable bioink, suitable for 3D bioprinting. The company envisions a wide range of applications for dECM-based products, including:
* advanced tissue models for drug testing, personalized therapies, or cosmetic testing,
* production of biomembranes for surgical purposes,
* fillers for aesthetic medicine,
* wound dressings,
* professional dermocosmetics
The company seeks international partnerships with industry-specific entities that are interested in collaboration in any form. - Advantages and Innovations
-
The main advantages of the developed technology stem from:
1. Scalability of the process.
2. Detergent-free approach.
3. High retention of the ECM components.
These advantages give us a strong basis to build a highly innovative company focused on ECM-based products, with a worldwide reach. Due to a strong scientific background, the founders have indentified an emerging trend in biomaterials for tissue engineering, and aim to capitalize on first-mover advantage in the field of dECM-based biomaterials. - Stage of Development
- Available for demonstration
- Sustainable Development Goals
- Goal 9: Industry, Innovation and Infrastructure
- Goal 3: Good Health and Well-being
- Goal 8: Decent Work and Economic Growth
- Goal 12: Responsible Consumption and Production
- Goal 17: Partnerships to achieve the Goal
- IPR status
- IPR granted
- IPR notes
- P.437380
Partner Sought
- Expected Role of a Partner
-
We are looking for the industry-specific partners willing to colaborate towards commercialization of the dECM-based products including:
1. Investors: to provide financial support and market insights for product development, marketing and scaling operations.
2. Manufacturers of biomaterials-based products: to co-develop products or supply dECM from tissues-of-interest.
3. Big companies or SMEs willing to participate in joined grant applications. - Type and Size of Partner
- Big company
- SME 11-49
- SME 50 - 249
- R&D Institution
- SME <=10
- Type of partnership
- Commercial agreement
- Investment agreement
Dissemination
- Technology keywords
- 06002004 - Protein Engineering
- 06002005 - Genetic Engineering
- 06002002 - Cellular and Molecular Biology
- 06001024 - Medical Biomaterials
- Market keywords
- 05005022 - Other clinical medicine
- 04006 - Cellular and Molecular Biology
- 04008 - Genetic Engineering
- Sector Groups Involved
- Health
- Targeted countries
- All countries